Introduction
Oncogenic transformation implies that normal cells lose their control over regulated cell proliferation, a process that in many occasions is accompanied by dysregulation of apoptosis. Cell proliferation is characterized by the duplication of all the cellular components in a strict temporal order including not only DNA but also proteins and lipids among other structural components. In the particular case of lipids, it is well established that PC, the most abundant lipid of the membranes, is accumulated in S phase during the cell cycle as a periodic event previously to G2 phase and mitosis. This net accumulation of PC results from an interaction between cell cycle-dependent oscillations in the rates of PC biosynthesis and degradation during G1 phase (Lykidis and Jackowski, 2001) . PC is mainly generated through the CDP-choline pathway (also known as the Kennedy pathway), although a second metabolic route has been described in hepatocytes and yeast involving phosphatidylserine (PS) decarboxylation to phosphatidylethanolamine (PE), followed by tri-methylation to PC (Vance et al., 1997) .
PC metabolism through the Kennedy pathway is composed of four steps. It starts with the release of choline from PC by PLD or its uptake by passive diffusion or facilitated transport (Pelech and Vance, 1984; Man et al., 1994) . Then, ChoK converts choline into PCho (Wittenberg and Kornberg, 1953; Wieprecht et al., 1994) . ChoK is susceptible of phosphorylation by cAMPdependent kinase (PKA) in yeast, resulting in its upregulation (Kim and Carman, 1999) . Hormones and growth factors induce the transient activation of ChoK, an event that at least involves its transcriptional regulation (Warden and Friedkin, 1985; Uchida, 1994; Uchida, 1996; Hundertmark et al., 1999) . The third step, CTP : Phosphocholine cytidyltransferase (CT), converts CTP and PCho into CDP-Choline (CDP-Cho) (Weinhold et al., 1989) . CT is considered the rate-limiting step of this pathway. It has been reported to be regulated by either phosphorylation, translocation or expression (Davies et al., 2001; Golfman et al., 2001) . Next, CDP-Choline : 1,2-diacylglycerol-cholinephosphotransferase (CPT) converts CDP-Cho and diacylglycerol (DAG) into PC (Henneberry and McMaster, 1999) . CPT is susceptible of a compartmental regulation as well (Fernandez-Tome et al., 2002) . Finally, PC is susceptible of degradation into choline and phosphatidic acid (PA) by phospholipase D (PLD). At last, PLD is susceptible of additional regulation by growth factors and oncogenes (Foster and Xu, 2003) .
The strong control in the synthesis and degradation of PC is probably based on its dual function, as the main lipidic structural element of cell membranes, and as a source of important mitotic second messengers, such as PA and its derivatives Lyso-PA (LPA) and DAG (Billah and Anthes, 1990; Nishizuka, 1992; Zeisel, 1993) . PA, LPA and DAG are mitogenic for a large number of cell types and their respective signalling pathways have been identified (Moolenaar et al., 1986; Nishizuka, 1992; Finney et al., 2000) . On the other hand, PC impinges into the synthesis of SM through the regulation of the intracellular levels of choline and PCho (Ursini et al., 1985) , and is in equilibrium with two other abundant membrane phospholipids: PS (Kuge et al., 1986) and PE (Takahashi et al., 1987; Vance et al., 1997) . Ceramides, a by-product of SM metabolism, has been implicated in the regulation of apoptosis, differentiation and cell arrest (Bielawska et al., 1992; Dressler et al., 1992; Brindley et al., 1996; Hannun, 1996; Kolesnick, 2002) . Thus, PC metabolism may also be linked to these processes. This implies that the maintenance of the status of PC is a critical event for the cell because its oscillations would have implications not only in the structural homeostasis of the membranes but also in signalling in cell proliferation and apoptosis.
ChoK inhibitors have been demonstrated to be potent antitumoral drugs both in vitro and in vivo (Jime´nez et al., 1995; Herna´ndez-Alcoceba et al., 1997 , 1999 Lacal, 2001; Ramirez de Molina et al., in press ). MN58b, used as a prototypic ChoK inhibitor, is rather specific towards ChoK (Rodrı´guez-Gonza´lez et al., 2003) . Here, we used MN58b to study the mechanistic antitumoral implications of ChoK inhibition, and demonstrate that inhibition of ChoK results in an unexpected strong differential effect on tumoral cells versus their normal counterparts. Inhibition of ChoK in tumoral cells promotes a nonreversible effect resulting in the strong induction of apoptosis. By contrast, inhibition of ChoK reversibly arrests normal cells with no apoptotic response. This differential response to ChoK inhibition constitutes the basis for the in vivo antitumoral activity of MN58b (Herna´ndez-Alcoceba et al., 1999; Ramirez de Molina et al., in press) . A temporary relationship of the events that take place under each cellular context, tumoral versus normal cells, as well as the rationale that explains this differential effect is provided.
Results

Effects of ChoK inhibition on G1/S transition in normal cells
The cell cycle machinery regulates the duplication of all elements in the cell. This process is ordered in a sequential manner that determines the time and phase of duplication for each specific component. In order to identify the specific phase of the cell cycle where MN58b executes its action, we analysed the effects of ChoK inhibition along the cell cycle. We first searched for a temporal relationship in the variation of the intracellular levels of PCho, DNA synthesis and increment of total lipids in synchronically stimulated primary lymphocytes. DNA synthesis and the increase in the intracellular levels of PCho occurred within similar time frames, while the peak increment in total lipids was clearly displaced to a later time (Figure 1a) .
Normal, primary lymphocytes are confined to an arrest in G0/G1 after MN58b treatment (Figure 1b) . Suboptimal concentrations of ChoK inhibitor render partial inhibition of ChoK activity (Figure 1c ), which correlates with a partial inhibition of cell proliferation (Figure 1d ).
This suggests that G0/G1 is the phase where ChoK inhibition may be more relevant. As shown in Figure 2a , synthesis of DNA was drastically affected by inhibition of ChoK activity by MN58b after stimulation of quiescent primary lymphocytes with PHA and IL-2. Also, a clear interference with the mitotic activation of RNA synthesis by PHA and IL-2 was observed ( Figure 2b ). However, MN58b had no significant inhibitory effect on the basal synthesis of RNA in nonstimulated primary lymphocytes (Figure 2c ). These results are indicative of a specific interference with the mitotic activation of RNA synthesis with no effect over basal RNA synthesis.
These observations suggest that inhibition of ChoK interferes with cell proliferation before the S phase is initiated. This is in keeping with the observation that quiescent normal cells treated with MN58b stay arrested despite mitotic stimulators (Figure 1b) . Consistent with this, activation of quiescent primary lymphocytes by PHA and IL-2 in the presence of MN58b results in a defect on pRb phosphorylation (Figure 3a) . Suboptimal concentrations of MN58b that render partial inhibition of ChoK activity ( Figure 1c ) correlated with a partial inhibition of cell proliferation ( Figure 1d ) and a partial phosphorylation of pRb (data not shown).
We analysed further the effects of MN58b treatment during activation of lymphocytes with PHA and IL-2. Stimulation of primary lymphocytes with PHA and IL-2 induces the activation of some critical signalling pathways that activate proliferation such as AKT and STAT-5A/B (Brennan et al., 1999) . Normal activation profiles were observed at initial time frames (up to 12 h), but they were drastically affected by ChoK inhibition at later times (Figure 3b) , impinging into the progression of G1 phase. Disruption of normal G1 progression was determined by estimation of the levels of c-Fos, cyclin D3, cyclin E, Cdk-2, p21 and p27 (Sheaff et al., 1997; Flores et al., 1999; Tsukiyama et al., 2001) , which promotes the consequent phosphorylation of pRb in G1-S transition (Figures 3 and 4) . ChoK inhibition resulted in the inhibition of c-Fos expression, an important early gene in lymphocytes activation (Flores et al., 1999) (Figure 3b) , and the interruption of the expression of cyclins D3 and E (Figure 4a ), and p21 (CIP-1) (Figure 4b ). By contrast, there is no significant effect on the increase of the expression in Cdk-2 (Figure 4a ), the typical decrease of p27 (KIP 1) or the lack of expression of p16 (INK 4a) (Figure 4b ) (Tsukiyama et al., 2001) . Finally, at times where pRb was clearly not phosphorylated (Figure 5b) , there was no alteration in the levels of p57 (Kip2), p53, total Cdk-2, phosphorylated-160-Cdk-2, p21 (Figure 5c, d) or cyclin E (data not shown). Thus, MN58b treatment interferes with the activation of lymphocytes by affecting the activation of AKT and STAT5, and by inhibiting the induction of c-Fos, cyclin E, cyclin D3 and p21. All these events render the lack of phosphorylation of pRb and a strong arrest in Go.
Effects of ChoK inhibition in the balance of phospholipid metabolites in normal cells PC synthesis is tightly regulated in a cell cycle-dependent manner. Inhibition of ChoK by MN58b may have drastic consequences in the regulation of lipid metabolites (in particular, in the regulation of the Kennedy pathway), which may be translated into a negative effect on the cell cycle. Thus, the effect in lipid metabolism was analysed at the same time frame than the observed alterations in pRb phosphorylation described above. As expected, inhibition of intracellular ChoK activity had a drastic inhibition of the de novo PCho synthesis even at 12 h of treatment (Figure 6a ), which is also translated to a lesser extent to the whole pool of intracellular prelabelled PCho (Figure 6b ). By contrast, there was no significant reduction in the levels of CDP-Cho ( Figure 6 ). No significant effect on the total levels of PC, 
Effects of ChoK inhibition in phospholipid metabolites in tumour cells
We have used Jurkat cells, derived from a human lymphoma, as an appropriate model to compare with human primary lymphocytes. In contrast to normal cells, ChoK inhibition by MN58b has no effect on phosphorylation of pRb ( Figure 7) . Furthermore, the cells do not arrest in G0/G1, but are promoted to apoptosis as revealed by the degradation of DNA and PARP ( Figure 7 ). Thus, ChoK inhibition in primary normal cells and tumour cells causes differential responses, since primary cells are reversibly arrested at G0/G1 but tumour cells are prompted to apoptosis. This different behaviour is based in a differential molecular signalling manifested by a distinct effect on pRb regulation.
We next sought to further investigate the mechanism by which MN58b triggers apoptosis specifically in tumour-derived cell lines. To that end, we asked whether activation of caspase 9 was a previous event to the degradation of PARP as a consequence of activation of the apoptosome, in a mitochondrial-dependent manner (Green, 2000; Wang, 2001) . As shown in Figure 7 , activation of caspase 9 was observed after degradation of PARP. Furthermore, no disruption in the expression levels of p53, nor the status of p53 phosphorylation, was observed ( Figure 7 ), or BCL-2 levels (data not shown). These results point to the possible absence of mitochondrial components as an essential step in the induction of apoptosis by ChoK inhibition in Jurkat cells. In keeping with this, MCF-7 cells lacking casp-3 (Janicke et al., 1998; Ruiz-Ruiz, 2002) , or K562 and SAOS-2 cells, which are p53 defective (Hudson et al., 1995) , were efficiently induced to apoptosis within equivalent time frames as other tumor-derived cell lines (data not shown). Finally, MN58b-induced apoptosis in MCF-7 cells stably transfected with Bcl-2, while remaining insensitive to UV irradiation-induced apoptosis (data not shown) (Ruiz-Ruiz, 2002) . All these results taken together suggest that MN58b-induced apoptosis follows a mechanism that may be independent of that involving the apoptosome and mitochondria.
ChoK inhibition and lipid metabolites balance in tumour cells
Inhibition of ChoK by MN58b in primary cells produces a great reduction of de novo PCho synthesis, and as a consequence a reduction in the whole intracellular pool of PCho ( Figure 6 ). No alteration is observed in the levels of CDP-Cho, PC or SM in a time frame that normal cells are efficiently arrested and pRb activation is fully blocked as determined by its phosphorylation status (Figures 3 and 5 ). By contrast, MN58b treatment efficiently promots tumour cells to apoptosis and no inhibition of the phosphorylation of pRb is observed ( Figure 7 ). Thus, a comparative study of the effects on the Kennedy pathway in normal and tumour-derived cells was carried out in an attempt to understand the differential effects on both types of cells, normal tumour cells.
The effects on lipid metabolites in Jurkat cells by MN58b treatment were analysed at the same time frame that PARP degradation was observed as shown in Figure 7 . Under these conditions, the intracellular pool (Figure 8b ). At last, the levels of PC and SM were also affected significantly (Figure 8c, d) . A further consequence of this effect was the imbalance of the levels of ceramides, a product of SM metabolism. As shown in Figure 9a , the levels of ceramides were dramatically increased specifically in Jurkat cells after ChoK inhibition, while only moderately altered in normal primary lymphocytes (Figure 9b ). Ceramides have been associated with the induction of apoptosis in several cell types (Hannun, 1996; Kolesnick, 2002) . Thus, ceramides production in response to MN58b treatment constitutes a critical differential effect of ChoK inhibition in normal versus tumor-derived cells. Indeed, there is no significant change in SM and PC levels in primary normal lymphocytes (Figures 6 and  9d) , while tumour cells suffer a drastic reduction in SM and PC (Figures 8c, d and 9c) , along with the increase in ceramides (Figure 9a, b) . Finally, we extended this observation to other cell systems. The basal levels of PCho as well as the effects of MN58b treatment in primary human epithelial mammary cells (HMEC) were compared to HT29 and HeLa cells. As shown in Table 1 , similar results were obtained in primary lymphocytes/ Jurkat and in HMEC/HT-29/HeLa systems. Normal cells were arrested in G0, while all tumor cells were induced to apoptosis parallel to the increase in ceramides as a consequence of the lipid metabolism wobble.
Discussion
Choline, the substrate of ChoK, is an essential nutrient for humans required for the synthesis of PC and SM, basic components of cell membranes in all eukaryotic cell types (Zeisel et al., 1991) . The main stream to convert choline into PC and SM metabolism is through the Kennedy pathway, starting with its phosphorylation by ChoK. An increment of the intracellular levels of PCho takes place before phospholipids accumulation, since PCho is the main precursor of PC (Figure 1a) . The temporal connection of increased PCho levels with DNA synthesis establishes the possibility of a signalling relationship between the G1-S transition and the intracellular levels of PCho (Figure 1a) . Therefore, PCho might be an indicator of the cellular status in the G1-S transition.
Alteration of the cell cycle in transformed cells results in an increase in promotion of cell division, and concomitantly, an increase in the synthesis of all required metabolic elements. Cell membranes also participate in this process since the increased in the proliferation rate demands an increment of intermediate Mechanism of action of choline kinase inhibitors A Rodríguez-González et al metabolites for membrane synthesis. In this context, the increase of intracellular levels of PCho in tumor cells is reasonable as the main precursor of PC. This is in keeping with the regulation of the Kennedy pathway by mitotic signalling and its alteration during the transformation process as previously reported (Lacal, 2001 ). We provide evidence that ChoK inhibitors in normal cells interfere with the activation of pRb, the main checkpoint in the transition G1-S (Weinberg, 1995) , resulting in the arrest of primary normal cells (Figures  3a and 5b) . As expected, ChoK inhibitors induce a drastic inhibition of ChoK activity (Figures 1c and 6a) , resulting in a decrease in the intracellular PCho pool (Figure 6b ). However, there is no significant effect in any of the major phospholipids such as PC and SM (Figure 6c-f) . Thus, a mild decrease in intracellular PCho could be sufficient to sensitize cells for a block in the phosphorylation of pRb within 18-24 h (Figures 3a  and 5b ), triggering the arrest of primary cells in G0/G1 (Figures 1b and 5a ). This impinges back into lipid metabolism, reducing the requirements for lipid synthesis. This would explain the absence of alterations in the status of lipid metabolites for at least 36 h (Figures 6e, f  and 9d) . Furthermore, at this same time frame, there is no change in the expression of critical elements in cell cycle regulation (Sherr, 1999) such as p21 (CIP 1), p57 (KIP 2), p53, CDK-2, phospho(160)-CDK-2 (Figure 7c,  d) or cyclin E (data not shown) in proliferating primary lymphocytes treated with MN58b. By contrast, ChoK inhibition affects AKT and STAT5 activation, the expression of c-Fos, as well as a clear interference in the normal increment of expression of cyclin D3, cyclin E and p21 (Figures 3 and 4) , events associated with the activation of lymphocytes (Nourse et al., 1994) . All these results explain the defect of pRb phosphorylation during the activation and proliferation of primary normal lymphocytes in the presence of ChoK inhibitors (Figures 3a and 5b) . They also suggest a feedback mechanism that regulates PC synthesis, resulting in the maintenance of the balance in the Kennedy pathway and the status of SM levels.
In contrast with the above results in primary cells, inhibition of ChoK activity in tumor-derived cells results in the promotion of apoptosis (Figure 7) . A surprising finding was contrary to what was observed in normal primary cells, ChoK inhibition had no effect on pRb phosphorylation (Figure 7 ), and as a consequence, cells do not arrest in G1/G0. This is not the only major difference between primary cells and tumor cells. When the alterations in the balance of lipid metabolites in the Kennedy pathway were investigated, several critical changes were observed (Figure 8) . First, the intracellular pool of PCho was drastically affected by ChoK inhibition, in contrast with normal primary cells that showed a moderate reduction. The effect in PCho was translated to CDP-Cho in the following 12 h and this effect was further translated into a decrease in PC and SM levels 12 h later only in tumour cells. A final consequence was a specific drastic increase in the intracellular levels of ceramides in tumour cells in contrast with a mild increase found in the primary cells under similar conditions (Figure 9a, b) . This increment in ceramides may result in stress, apoptosis or cell cycle arrest through the ceramides activated effectors (CAE) (Hannun, 1996; Kolesnick, 2002; Ruvolo, 2003) . Further studies will assign the specific ceramide-dependent signalling modulators responsible for MN58b effects. The above mechanism explains the differential effect of MN58b between normal primary and tumour cells, and also the antitumour activity of ChoK inhibitors. It also justifies its nontoxic, reversible effects on primary normal cells.
We have also investigated the specific pathway used for the induction of apoptosis in tumor cells. To that end, we analysed the temporal order of activation of caspase 9 and degradation of PARP. The putative alteration in the expression p53 was also investigated 
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A Rodríguez-González et al ( Figure 7 ). Activation of caspase 9 determined by its degradation was observed after PARP degradation. Furthermore, there was no alteration of the levels of expression or phosphorylation of p53 ( Figure 7) . Also, MCF-7 cells overexpressing Bcl-2 were efficiently promoted to apoptosis by MN58b (data not shown), but are resistant to induction of apoptosis by UV irradiation (Ruiz-Ruiz, 2002) . It has been suggested that a metabolic check-point in G1 may function as a sensor for the correct metabolic status of the cell before proliferation starts. This mechanism (Jarvis et al., 1994; Dbaibo et al., 1995; Hannun, 1996; Lacal 1997; Flores et al., 1998; Spiegel and Kolesnick, 2002; Ruvolo, 2003) may act as a switch for the promotion of G1-S transition, cell arrest or induction of apoptosis. This sensor will be able to integrate the information on the intracellular levels of the most critical metabolic and signalling lipid messengers such as PA, DAG, PCho and ceramides. In keeping with this, slight increments in ceramides in combination with mitotic signalling generate an arrest in G0/G1 in primary lymphocytes, dephosphorylation of pRb (Flores et al., 1998) and reversible arrest in G0/G1 (Rodrı´guez-Gonza´lez et al., 2003). All these results are consistent with our findings and with inhibitors that affect other enzymes and metabolites of the Kennedy pathway (Wieder et al., 1998) .
In tumour cells, the absence of a G0/G1 arrest by ChoK inhibition keeps the requirement of the PC demand switched on, resulting in the alteration of the lipid balance (Figures 7 and 8) . The Kennedy pathway is drastically affected because the synthesis of the main precursor of PC is inhibited. This drives the tumor cells into a metabolic wobble. A consequence of this metabolic demand is the progressive increment in the intracellular levels of ceramides and the promotion to apoptosis. Similar results have been described when inhibition of PC synthesis was achieved by alternative methods. Thus, hexadecylphosphocholine (HePC), an inhibitor of CT, leads to a decrease not only in PC but also in SM, and the accumulation of ceramides (Sillence and Allan, 1998; Wieder et al., 1998) , resulting in an atypical apoptosis (Cui and Houweling, 2002) . The same effect can be generated by choline deprivation in the diet, the primary substrate for the Kennedy pathway (Holmes-McNary et al., 1997) . In some cellular systems, such as PC12 cells, choline depletion induced apoptosis associated with a 50% reduction of PC content, but also 
with a considerable decrease of other choline-containing lipids, such as SM (Yen et al., 1999) . This decrease of PC and SM is accompanied by an increase of DAG and ceramides, which renders activation of caspase 3 (Yen et al., 1999 (Yen et al., , 2001 ). Thus, affection of the Kennedy pathway by alternative strategies results in a similar situation to that described in our study, where inhibition of ChoK in tumor cells by MN58b induces apoptosis. An alternative pathway to generate PC implies the methylation of PE by phosphatidylethanolamine-N-methyl-transferase (PEMT) (Vance et al., 1997) . However, this pathway is not relevant in mammalian cells as demonstrated by restoration of PC synthesis by PEMT transfection experiments in cells rendered temperature-sensitive mutant for CT (MT58 cell line) (Esko et al., 1981 (Esko et al., , 1982 Houweling et al., 1995; Cui et al., 1996) . The inability of PEMT to rescue MT58 cells under restrictive temperature from apoptosis suggests that the PC species generated from the Kennedy pathway and the PEMT pathway are functionally different (Cui and Houweling, 2002) . Indeed, the PC species derived from PE methylation contain longer and more unsaturated fatty acid chains than the PC species generated through the Kennedy pathway (DeLong et al., 1999) . The only PC capable of rescuing MT58 cells at the nonpermissive temperature from apoptosis is PC generated through the Kennedy pathway (Esko et al., 1982; Ostrander et al., 2001) . Changes in the nature of PC in membranes may cause alterations in the fluidity, structural integration and association of membrane proteins, vesicular traffic, affinity and activity of lipases (DeLong et al., 1999) .
We conclude that normal cells are reversibly arrested by ChoK inhibition through an efficient inhibition of the cell cycle machinery. By contrast, ChoK inhibition in tumour cells promotes apoptosis. This differential derives from a metabolic wobble generated as a consequence of the impossibility of tumor cells to be arrested. A reasonable explanation for this effect is that when tumor cells attempt to provide PCho as a requirement for PC synthesis, it results in the hydrolysis of SM and the generation of both the required PCho, and ceramides, a lethal metabolite that promotes apoptosis. Alternatively, the accumulation of ceramides could result also through its synthesis by ceramide synthase. This would be a consequence of the reduced availability of PC to serve as the donor of PCho for the synthesis of SM. Since a drastic reduction in the levels of SM is observed at the same time that the increase in ceramides takes place, the involvement of a sphygomyelinase seems more likely to occur. The accumulation of ceramides takes place before PC and SM are affected by MN58b treatment, but simultaneous to the observed CDP-Cho reduction. This opens the possibility for the initiation of apoptosis promotion (12-24 h). However, under similar conditions, inhibition of ChoK in primary cells promotes an arrest in G0/G1 that reduces the demand of PC, avoids the detrimental effect on PC synthesis and the concomitant metabolic wobble. Further studies to identify the origin of ceramides under these conditions will clarify this issue. This different effect of ChoK inhibition discriminates among tumor and nontumor cells, which is the great goal of this rational strategy in comparison to traditional chemotherapy. We provide in this study the rationale for the potential clinical use of ChoK inhibitors.
Materials and methods
Cell culture and reagents
All cell lines used in this study were maintained under standard conditions of temperature (371C), humidity (95%), and carbon dioxide (5%). The following cell lines were used: HeLa (ATCC CCL 2, human cervix adenocarcinoma) and HT-29 (ATCC HTB 38, human colon adenocarcinoma), which were maintained in DMEM supplemented with 10% FBS; HMEC (Clonetics, CC-251 primary human mammary epithelial cells) were maintained in MEBM supplemented with bullet kit (Clonetics, CC-3150); Jurkat cells (ATCC CRL 8163, human lymphoma) were maintained in RPMI supplemented with 10% FBS; normal human peripheral lymphocytes were isolated from the circulating blood of healthy adults by gradient centrifugation with Histopaque-1077 (Sigma Diagnostics ref: H-8889) . Lymphocytes were cultured in RPMI supplemented with 10% FBS and 2 mg/ml of PHA (Lectin, Sigma ref: L4144) during 24 h, afterwards the medium were removed and PHA was substituted by IL-2 (50 U/ml) (Interleukin-2, Sigma ref:
T-3267).
Intracellular levels of PCho
The adherent cells HT-29, and HeLa cells were seeded on six-well plates at a density of 10 5 cells/well (Falcon; Becton Dickinson, Flankin Lakes, NJ, USA). HMEC cells were seeded at a density of 96 Â 10 3 cells/plate. Cells were incubated for 2 days and labelled during 24 h with [methyl- 14 C]Choline chloride, ICN pharmaceuticals (Inc), rinsed in ice-cold TD buffer (137 mM NaCl, 5 mM KCl and 20 mM Tris pH ¼ 7.4) and fixed with 16% ice-cold trichloroacetic acid. Jurkat, HT-29 and HeLa cells (25 Â 10 4 /ml per well) and primary lymphocytes (10 6 /ml per well) were seeded on six-well plates. Cells were centrifugated after 24 h labelling, rinsed with TD and fixed with 16% trichloroacetic acid. Water-soluble material containing Cho, PCho and CDP-Cho was washed three times with four volumes of diethylether, dried under vacuum, and resuspended in water. Samples were resolved by TLC on 60 A plates (Whatman, Clifton, NJ, USA), using 0.9% NaCl : methanol : ammonium hydroxide (50 : 70 : 5; v/v/ v) . Radioactivity corresponding to PCho was automatically quantified by an electronic radiography system (Instantimager; Packard, Meriden, CT, USA).
Cell proliferation assays
Proliferation assays were performed by crystal violet as previously published (Herna´ndez-Alcoceba et al., 1997) . Cells were seeded at a density of 20 Â 10 3 cells per well. For nonadherent cell lines, washings were preceded by fixation with TCA at 16%. 14 C]Choline chloride from ICN pharmaceuticals(Inc.), in the presence or absence of MN58b treatment. Cells were centrifugated and rinsed with ice-cold TD buffer (137 mM NaCl, 5 mM KCl and 20 mM Tris pH 7.4) previous to being fixed with 16% ice-cold trichloroacetic acid. Trichloroacetic acid-soluble material containing Cho, PCho and CDP-Cho was washed three times with four volumes of diethylether, dried under vacuum, and resuspended in water. Samples were resolved by TLC as indicated above for intracellular levels of PCho.
Cell cytometry analysis
Adherent cell lines were seeded at a density of 40 Â 10 3 cells per well, with the exception of HMEC, seeded at 96 Â 10 3 cells per well, and treated 24 h later. Cells were trypsinized and centrifugated at 400 g for 5 min, diluted in 1 ml PBS and mixed with 9 ml of 70% ethanol. The samples were diluted in 1 ml PBS (2.5 mM C 6 H 5 Na 3 O 7 , 0.01% TX 100, 20 mg propidium iodide). Suspension cells followed an equal process but the inoculation was 25 Â 10 4 /ml per well. A Beckton Dickinson FACs SCAN was used.
DNA and RNA synthesis
Primary lymphocytes (10 6 cells/ml per well) were seeded on 24-well plates. Primary lymphocytes were maintained in RPMI supplemented with 10% FBS and 2 mg/ml of PHA for 24 h, then the medium was removed and PHA treatment was substituted by IL-2 (50 U/ml) for the next 24 h. At 3 or 4 h before processing, 1 mCi/ml methyl-[ 3 H]thymidine (DNA synthesis) or methyl-[ 3 H]uridine (RNA synthesis) was added. Cells were centrifuged at 13 000 g for 5 min and rinsed with TD before fixing them in 16% TCA. Incorporated thymidine was determined by adding 0.25 N NaOH and counting in a Liquid Scintillation Counter (LKB Wallac 1214 RACKBETA).
Western blot analysis
Cells were lysed in lysis buffer (150 mM NaCl, 0.5% NP40, 0.5% DOC, 0.1% SDS, 50 mM Tris HCl pH 7.5, 15 mM bglicerophosphate, 10 mM Na 3 P 2 O 4 , NaF 20 mM, Na PPi 1 mM, 1 mg/ml aproteinin, 1 mg/ml leupeptin, 1 mM PMSF). Lysates were centrifuged at 13 000 g for 20 min at 41C and quantified by Bio-Rad kit. Same amounts of total protein were loaded into SDS-PAGE acrylamide gels and resolved proteins were transferred onto nitrocellulose membranes.
The following antibodies were used: anti-phospho-AKT (P-ser472/473/474) (BD PharMingen), anti-p53 (Sigma), antiphospho-pRb (P-ser807/811) (Cell Signalling Tecnology), anti-Rb (Santa Cruz Biotechnology), anti-p16 (Novo Castra), anti-cyclin D3 (BD PharMigen), anti-cdk2 (BD PharMigen), anti-p27 (BD PharMingen), anti-p21 (Santa Cruz Biotechnology), anti-phospho-cdk2 (P-thr 160 Santa Cruz Biotechnology), anti-phospho-STAT5a/b (P-tyr699, P-tyr 696 Cell Signalling Technology), anti-CASP9 (Santa Cruz Biotechnology), anti-PARP (Santa Cruz Biotechnology) and anti-BCL-2 (Santa Cruz Biotechnology).
Lipid analysis
Lymphocytes (typically 10 6 /well) and Jurkat, HMEC, HT-29 and HeLa cells were seeded on six-well plates and incubated for 2 days in the presence of 1 mCi/ml [ 
Measurement of intracellular ceramides
Lymphocytes (typically 10 6 /well) and Jurkat cells were seeded on six-well plates, and 24 h later they were incubated for 2 days in the presence of 1 mCi/ml of [ 14 C]Serine. Afterwards, they were treated with MN58b in the presence of [ 14 C]Serine. Lipids were harvested by a solution based on chloroform : methanol : water (36 : 30 : 6, v : v : v) . The organic phase was dried in a concentrator under N 2 flow at 371C. Samples were resuspended in chloroform : methanol (1 : 1, v : v) and lipids were separated by TLC in chloroform : methanol : ammonium (2 M) (65 : 25 : 4, v : v : v) . Quantification of lipids was carried out by Instantimager.
